Climb Bio said its anti-CD19 antibody budoprutug is moving through multiple immune-mediated disease programs, with fresh subcutaneous formulation data showing robust B-cell depletion in healthy volunteers and several clinical readouts lined up for 2026.
The company said depletion with the subcutaneous version was similar to intravenous dosing at matched doses, and that the formulation was generally safe and well tolerated. Those results, Climb Bio said, support advancing the drug into studies in patients with autoimmune disease.
Budoprutug’s pipeline is active across three programs. In primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, studies are enrolling to plan. Climb Bio said it expects initial data from the immune thrombocytopenia trial in June, with additional higher-dose data by year-end. Initial data from the primary membranous nephropathy study is expected in the fourth quarter of 2026, along with initial data from the lupus study.
The company also said it has received fast track designation for the primary membranous nephropathy program.
Dose ranges in the ongoing studies span 200 mg to 1,000 mg in primary membranous nephropathy, 250 mg to 1,000 mg in immune thrombocytopenia, and 100 mg to 600 mg in systemic lupus erythematosus.
Climb Bio described budoprutug as a differentiated CD19 monoclonal antibody and said the target is broadly expressed across the B-cell lineage, including early B cells and antibody-producing cells. The company said it sees the approach as potentially capable of deeper peripheral and tissue-level B-cell depletion than anti-CD20 strategies.
The company also highlighted early clinical data in primary membranous nephropathy as supporting potential for long-term disease control. As a result of these announcements, the company's shares have moved 3.92% on the market, and are now trading at a price of $10.07. Check out the company's full 8-K submission here.
